These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24416385)

  • 41. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
    Huynh H; Choo SP; Toh HC; Tai WM; Chung AY; Chow PK; Ong R; Soo KC
    Curr Cancer Drug Targets; 2011 Oct; 11(8):944-53. PubMed ID: 21834756
    [TBL] [Abstract][Full Text] [Related]  

  • 42. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
    Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
    Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
    Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
    J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.
    Lai YL; Wang KH; Hsieh HP; Yen WC
    J Biomed Sci; 2022 Jan; 29(1):5. PubMed ID: 35062934
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma.
    Lau CK; Yang ZF; Lam SP; Lam CT; Ngai P; Tam KH; Poon RT; Fan ST
    Cancer Biol Ther; 2007 Dec; 6(12):1900-7. PubMed ID: 18059167
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development.
    Gu Q; Zhang B; Sun H; Xu Q; Tan Y; Wang G; Luo Q; Xu W; Yang S; Li J; Fu J; Chen L; Yuan S; Liang G; Ji Q; Chen SH; Chan CC; Zhou W; Xu X; Wang H; Fang DD
    Oncotarget; 2015 Aug; 6(24):20160-76. PubMed ID: 26062443
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis.
    Yu T; Yu J; Lu L; Zhang Y; Zhou Y; Zhou Y; Huang F; Sun L; Guo Z; Hou G; Dong Z; Wang B
    Cell Oncol (Dordr); 2021 Aug; 44(4):821-834. PubMed ID: 33974236
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
    Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
    BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.
    Nishina S; Yamauchi A; Kawaguchi T; Kaku K; Goto M; Sasaki K; Hara Y; Tomiyama Y; Kuribayashi F; Torimura T; Hino K
    Cell Mol Gastroenterol Hepatol; 2019; 7(1):115-134. PubMed ID: 30510994
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma.
    Giovannini C; Baglioni M; Baron Toaldo M; Ventrucci C; D'Adamo S; Cipone M; Chieco P; Gramantieri L; Bolondi L
    Oncotarget; 2013 Oct; 4(10):1618-31. PubMed ID: 24113128
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.
    Wild AT; Gandhi N; Chettiar ST; Aziz K; Gajula RP; Williams RD; Kumar R; Taparra K; Zeng J; Cades JA; Velarde E; Menon S; Geschwind JF; Cosgrove D; Pawlik TM; Maitra A; Wong J; Hales RK; Torbenson MS; Herman JM; Tran PT
    PLoS One; 2013; 8(6):e65726. PubMed ID: 23762417
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Auphen and dibutyryl cAMP suppress growth of hepatocellular carcinoma by regulating expression of aquaporins 3 and 9 in vivo.
    Peng R; Zhao GX; Li J; Zhang Y; Shen XZ; Wang JY; Sun JY
    World J Gastroenterol; 2016 Mar; 22(12):3341-54. PubMed ID: 27022216
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patient-derived multicellular tumor spheroids towards optimized treatment for patients with hepatocellular carcinoma.
    Song Y; Kim JS; Kim SH; Park YK; Yu E; Kim KH; Seo EJ; Oh HB; Lee HC; Kim KM; Seo HR
    J Exp Clin Cancer Res; 2018 May; 37(1):109. PubMed ID: 29801504
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of 9-nitrocamptothecin liposomes: anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo.
    Zheng S; Chang S; Lu J; Chen Z; Xie L; Nie Y; He B; Zou S; Gu Z
    PLoS One; 2011; 6(6):e21064. PubMed ID: 21695227
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1.
    Zhou Y; Huang Y; Dai T; Hua Z; Xu J; Lin Y; Han L; Yue X; Ho L; Lu J; Ai X
    Biomed Pharmacother; 2021 Jan; 133():111030. PubMed ID: 33378944
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MiR-30e-3p Influences Tumor Phenotype through
    Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
    Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma.
    Leung HW; Lau EYT; Leung CON; Lei MML; Mok EHK; Ma VWS; Cho WCS; Ng IOL; Yun JP; Cai SH; Yu HJ; Ma S; Lee TKW
    Cancer Lett; 2020 Apr; 476():48-56. PubMed ID: 32061952
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma.
    Tan W; Luo X; Li W; Zhong J; Cao J; Zhu S; Chen X; Zhou R; Shang C; Chen Y
    EBioMedicine; 2019 Feb; 40():446-456. PubMed ID: 30594557
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma.
    Hou H; Sun H; Lu P; Ge C; Zhang L; Li H; Zhao F; Tian H; Zhang L; Chen T; Yao M; Li J
    Mol Cancer Ther; 2013 Dec; 12(12):2874-84. PubMed ID: 24130050
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
    Schmieder R; Puehler F; Neuhaus R; Kissel M; Adjei AA; Miner JN; Mumberg D; Ziegelbauer K; Scholz A
    Neoplasia; 2013 Oct; 15(10):1161-71. PubMed ID: 24204195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.